ALLR

Allarity Therapeutics, Inc. (ALLR) - Q1 2025 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended March 31, 2025. Allarity Therapeutics, Inc. is a clinical-stage pharmaceutical company developing personalized cancer treatments using its proprietary Drug Response Predictor (DRP®) technology. The Company's principal operations are located in Denmark, with a U.S. presence in Florida. The filing reflects retroactive adjustments for 1-for-20 and 1-for-30 reverse stock splits executed in April and September 2024, respectively.

Key Financial Metrics

Note: The Company reported no revenue for the period. Operating expenses consist of Research and Development ($1.40 million) and General and Administrative ($1.63 million).

Material Changes vs. Prior Period

• Reduced Net Loss: Net loss decreased by approximately $1.11 million compared to Q1 2024, driven primarily by a $1.20 million reduction in total operating expenses.
• Expense Reductions: R&D expenses declined by $0.77 million due to reduced manufacturing/supply costs and milestone payments. G&A expenses declined by $0.44 million due to lower professional service fees.
• Capital Raise: The Company raised approximately $9.7 million in net proceeds through its At-The-Market (ATM) facility during the quarter, selling 9.72 million shares. The ATM facility was fully utilized and terminated as of March 31, 2025.
• Other Income: Other income decreased by $0.09 million, largely due to the absence of the $0.42 million gain from the change in fair value of warrant liabilities recorded in Q1 2024.

Outlook, Risks, and Unusual Items

• Liquidity Position: Management estimates that existing cash, cash equivalents, and restricted cash of $27.7 million are sufficient to fund operations for at least the next 12 months. However, the Company expects to incur significant expenses to advance its lead candidate, stenoparib, and may require additional capital.
• SEC Settlement: The Company reached a final settlement with the SEC regarding an investigation into disclosures related to its Dovitinib NDA. A civil penalty of $2.5 million was paid on April 2, 2025 (subsequent to the period end). This amount was held in restricted cash as of March 31, 2025.
• Novartis Liability: Following the termination of a license agreement with Novartis in January 2024, the Company recorded approximately $5.3 million in total liabilities (Accounts Payable, Convertible Notes, and Accrued Liabilities) related to the agreement, which continue to accrue interest at 5% per annum.
• Share Repurchase: Subsequent to the quarter end (April 17 – May 6, 2025), the Company repurchased approximately 2.0 million shares for $2.1 million under its share repurchase program.
• Class Action Dismissal: A class action lawsuit filed in September 2024 regarding the Dovitinib NDA was dismissed in February 2025.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $27.7 million cash balance against the projected burn rate for the stenoparib clinical trials.
• Novartis Debt: Confirm the status of the $5.3 million liability to Novartis and the ongoing accrual of interest.
• ATM Termination: Note that the primary equity financing vehicle (ATM) is terminated; assess the Company's ability to raise future capital without this facility.
• SEC Penalty Impact: Confirm the full payment of the $2.5 million SEC penalty and any potential for further regulatory scrutiny.
• Stock-Based Compensation: Review the $0.14 million stock-based compensation expense and the remaining unrecognized expense of $0.8 million related to RSUs.